• Alice Neetha Amrita Vishwa Vidyapeetham University
  • Naveen Kumar Panicker
  • Neeraj Sidharthan


Objective: Rituximab therapy has become a promising therapeutic option for various non-malignant hematological disorders, after being reported
by many case reports. The objective of this study was to evaluate the immediate, infusion-related adverse drug events (ADE) of patients who received
rituximab for non-malignant, hematological disorders, in a tertiary healthcare center in India.
Methods: 14 patients (6 with primary immune thrombocytopenia, 4 with autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic
purpura, 1 with acquired hemophilia) were enrolled in the study. Patients were assessable for immediate infusion-related toxicity noted predominately
within 5 hrs of administration of rituximab infusion.
Results: Rituximab therapy was tolerated without major ADE. None of the patients experienced high-grade adverse events. The population who
experienced ADE (Grades 1-2) frequently had toxicities that suspected to result from infusion-related cytokine release syndrome (IRCRS) and
sometimes required cessation of the infusion and supportive intervention. Patients were monitored for 20 types of ADEs associated with IRCRS.
11 types of; mild to moderate (Grades 1 and 2) toxicities resulting from IRCRS were experienced by patients. Mean patients who experienced IRCRS
was 1.95 (13.93%), whereas majority of the study population tolerated therapy without IRCRS (86.78%). Among other toxicities, Grade 2 urinary tract
infection (UTI) (n=2, 14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia (n=1, 7.14%) were observed.
Conclusion: Toxicity profile of patients with non-malignant hematological disorders shows that rituximab is a safer biological therapy.
Keywords: Rituximab, Infusion related cytokine release syndrome, Adverse drug events, Immediate toxicities, Benign, Non-malignant, Hematological


1. Monograph of Rituximab. Available from: https://www.clinicalkey.
com/#!/content/drug_monograph/6-s2.0-2212. [Last accessed on
2013 Jul 11].
2. Aban C. Rituximab. Indian Pediatr 2011;48:627-32.
3. Lowinger J. Off-label use of rituximab. In: A Position Statement.
ed. Sydney: New South Wales Therapeutic Advisory Group Inc.,
NSW Health Department; 2007.
4. LaCasce AS, Castells MC, Burstein H, Meyerhardt JA, Drews RE,
Adkinson FN, et al. Infusion reactions to therapeutic monoclonal
antibodies used for cancer therapy. Available from: http://www. reactions to therapeutic monoclonal antibodies
used for cancer therapy. [Last accessed on 2015 Jan 11].
5. Package Insert. Rituxan
(Rituximab). San Diego, CA: IDEC
Pharmaceuticals Corporation; 2003.
6. Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20
monoclonal antibodies and their use in adult autoimmune hematological
disorders. Am J Hematol 2011;86(3):278-91.
7. Arnold DM, Dentali F, Meyer RM, Cook RJ, Crowther MA,
Sigouin C, et al. Systematic review: Efficacy and safety of rituximab
for adults with idiopathic thrombocytopenic purpura. Ann Intern Med
215 Views | 246 Downloads
How to Cite
Neetha, A., N. K. Panicker, and N. Sidharthan. “IMMEDIATE ADVERSE DRUG EVENTS WITH RITUXIMAB THERAPY IN NON-MALIGNANT HEMATOLOGICAL DISORDERS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 5, Sept. 2015, pp. 71-72,
Original Article(s)